Overview

To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-02-28

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the safety and tolerability of JPI-547 in combination with irinotecan as a third-line and beyond therapy for recurrent or metastatic gastric cancer

Phase:

PHASE1

Details

Lead Sponsor:

Onconic Therapeutics Inc.

Treatments:

Irinotecan
Pharmaceutical Preparations